| Tool Translational Research Projects | Stanford University | A Novel, Robust and Comprehensive Predictive Tool Using Human Disease-Specific Induced Pluripotent Stem Cells for Preclinical Drug Screening |
$975,000 |
| Conference II | Stanford University | Stanford Drug Discovery Symposium 2024 |
$15,000 |
| Conference II | Stanford University | Stanford Drug Discovery Symposium 2023 |
$50,000 |
| Conference II | Stanford University | Stanford Drug Discovery Symposium 2022 |
$29,408 |
| Conference II | Stanford University | 2018 Stanford Drug Discovery and Stem Cell Technology Conference |
$15,000 |
| Conference II | Stanford University | 2017 Stanford Drug Discovery and Stem Cell Technology Conference |
$2,359 |
| Conference II | Stanford University | Drug Discovery & Stem Cell Models for Cardiovascular Disease Conference |
$7,500 |
| Clinical Trial Stage Projects | Stanford University | A Phase I, Pilot Study of Human Embryonic Stem Cell-Derived Cardiomyocytes in PaTients with ChrOnic Ischemic Left VentRicular Dysfunction (HECTOR) |
$6,987,507 |
| Tools and Technologies III | Stanford University | Macaca mulatta as advanced model for predictive preclinical testing of engineered cardiac autografts and allografts |
$1,689,744 |
| Conference | Stanford University | Cardiovascular Tissue Engineering Symposium |
$25,000 |
| Conference | Stanford University | Cardiovascular Regenerative Medicine Symposium |
$9,000 |
| Tissue Collection for Disease Modeling | Stanford University | Tissue Collection for Accelerating iPSC Research in Cardiovascular Diseases |
$1,291,832 |
| Disease Team Therapy Development – Research | Stanford University | Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure |
$19,060,330 |
| Early Translational III | Stanford University | Heart Repair with Human Tissue Engineered Myocardium |
$4,395,080 |
| SEED Grant | Stanford University | In Vivo Imaging of Human Embryonic Stem Cell Derivatives and Tumorigenicity |
$623,634 |
